Pfizer Inc. (PFE)

43.81
0.31 0.71
NYSE : Health Technology
Prev Close 43.50
Open 43.83
Day Low/High 43.51 / 44.11
52 Wk Low/High 36.00 / 46.47
Volume 8.58M
Avg Volume 21.22M
Exchange NYSE
Shares Outstanding 5.55B
Market Cap 239.12B
EPS 1.90
P/E Ratio 22.67
Div & Yield 1.44 (3.26%)

Latest News

Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts

Pfizer Invites Public To View And Listen To Webcast Of July 30 Conference Call With Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.

Fed Up, Yet?

The narrative in the market is that we are waiting for the Fed decision on Wednesday -- but of course it's not that clear cut is it?

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting

Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

Bulls Walk the Market Up Slowly, but Keep One Eye on Fed

I'm inclined to add to Disney on today's weakness.

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer Nabs Array Biopharma in $11.4 Billion Takeover of Cancer Drug Specialist

Pfizer said Monday it has agreed to acquire Array Biopharma in an all-cash deal that values the cancer drug specialist at around $11.4 billion.

UniQure Jumps on Report It's Exploring a Possible Sale

UniQure Jumps on Report It's Exploring a Possible Sale

A report says the biotechnology company is exploring options including a potential sale amid interest from pharmaceutical companies looking to expand in gene therapy.

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

- Proposed acquisition strengthens Pfizer's innovative biopharmaceutical business and is expected to accelerate its growth trajectory particularly in the long term

Pfizer To Acquire Array BioPharma

Pfizer To Acquire Array BioPharma

Pfizer Inc. (NYSE: PFE) and Array BioPharma Inc.

How to Invest in Stocks: 14 Keys to Remember

How to Invest in Stocks: 14 Keys to Remember

Larry Swedroe lays out the fundamental truths of investing -- for beginners.

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Announces Results From XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study To Evaluate Methotrexate Withdrawal With A JAK Inhibitor

Pfizer Inc. (NYSE:PFE) announced today positive results from ORAL Shift, a Phase 3b/4 study in adult patients with moderately to severely active rheumatoid arthritis (RA).

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

Great News In An Oversold Market: Cramer's 'Mad Money' Recap (Friday 6/7/19)

It was a great week for stocks, says Jim Cramer. And he's got your game plan for next week.

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

PFIZER INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates The Officers And Directors Of Pfizer Inc. - PFE

NEW ORLEANS, June 7, 2019 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C.

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

PayPal, Tesla, Pfizer: 'Mad Money' Lightning Round

Jim Cramer takes a look at PayPal, Tesla, Pfizer, Americold Realty Trust, Continental Resources, United Natural Foods, Cintas, Splunk and more.

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Jeff Settleman, Ph.D., Joins Pfizer To Lead Oncology Research & Development

Pfizer Inc. (NYSE: PFE) announced today that Jeff Settleman, Ph.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #16 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Despite being ranked lower than the median among analyst picks of the Dow, Pfizer Inc ranks better than the median among analyst picks for the broader S&P 500 index components, claiming the #205 spot out of 500.

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Announces Top-Line Results From Phase 3 Trial Of LYRICA® (pregabalin) In Primary Generalized Tonic-Clonic Seizures

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA ® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary...

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Pfizer Gains After Being Named 'Top Pick' by Credit Suisse

Shares of Pfizer rise Thursday after the drugmaker is named a 'top pick' at Credit Suisse following a meeting the analysts had with Pfizer's management team.

TheStreet Quant Rating: B (Buy)